# Transgenic and Chimeric Mouse Facility

> **NIH NIH P30** · UNIVERSITY OF PENNSYLVANIA · 2022 · $2,136

## Abstract

PROJECT SUMMARY – Transgenic and Chimeric Mouse Facility
The Transgenic and Chimeric Mouse Facility (TCMF) at the Abramson Cancer Center (ACC) has been
continuously funded by the NCI CCSG since 1989 under the guidance of Dr. Stephen Liebhaber, Professor of
Genetics and Medicine. Dr. Liebhaber is an experienced investigator with considerable expertise in
technologies and experimental approaches that center on transgenic technologies, developmental biology, and
mammalian gene targeting. An experienced technical team, led by Dr. Jean Richa, provides expertise in a full
range of transgenic technologies, enabling the TCMF to regularly introduce new and improved services.
Among the services provided by the Transgenic and Chimeric Mouse Facility are generation of genetically
altered mice via direct genome editing (CRISPR/Cas9, and less frequently Zn finger and TALEN technologies),
by DNA microinjections into fertilized oocyte to create transgenic lines, or by generation of chimeric mice via
embryonic stem cell injection into blastocysts. The Transgenic and Chimeric Mouse Facility also carries out
embryo re-derivation, embryo and sperm cryopreservation, in vitro fertilization (IVF), and centralized
cryopreservation storage. The TCMF uses state-of-the-art laser conditioning of the zona to facilitate IVF and
has intracytoplasmic sperm injection capability on-line to complement IVF services. Newly developed services
during the current funding period include the major expansion of cryopreservation services with corresponding
expansion of the cryopreservation facility, integration of CRISPR/Cas9 direct genome modifications with a
newly established Perelman School of Medicine CRISPR core, and electroporation of DNA and RNA into
embryos to increase throughput and decrease wait time for TCMF services. ACC members accounted for 29 of
71 investigators (41%) using the Shared Resource during the most recent reporting period (07/01/18-
06/30/19). Additional Institutional (non-CCSG) support is provided for equipment maintenance and facility
infrastructure upgrades and maintenance. In one example of the supported high-impact research, the TCMF
generated a series of mouse cell lines, which were used to demonstrate opposing effects of the LIN28B-IMP1
axis on post-transcriptional regulation of canonical WNT signaling, with implications for intestinal homeostasis,
regeneration and tumorigenesis (Chatterji et al., Genes Dev, 2018). The TCMF provides cutting edge
technologies to generate transgenic mice needed for rigorous cancer research studies conducted by ACC
members.

## Key facts

- **NIH application ID:** 10330986
- **Project number:** 5P30CA016520-46
- **Recipient organization:** UNIVERSITY OF PENNSYLVANIA
- **Principal Investigator:** STEPHEN Aaron LIEBHABER
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $2,136
- **Award type:** 5
- **Project period:** 1997-01-15 → 2025-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10330986

## Citation

> US National Institutes of Health, RePORTER application 10330986, Transgenic and Chimeric Mouse Facility (5P30CA016520-46). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10330986. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*